Richard E Gilbert

Summary

Affiliation: University of Toronto
Country: Canada

Publications

  1. doi The endothelium in diabetic nephropathy
    Richard E Gilbert
    Keenan Research Centre of the Li Ka Shing Knowledge Institute, St Michael s Hospital, 61 Queen Street East, Toronto, Ontario, Canada, M5C 2 T2
    Curr Atheroscler Rep 16:410. 2014
  2. doi Augmenting endothelial repair in diabetes: role of bone marrow-derived cells
    Richard E Gilbert
    Keenan Research Centre of the Li Ka Shing Knowledge Institute, St Michael s Hospital, University of Toronto, Ontario, Canada Electronic address
    Can J Diabetes 37:315-8. 2013
  3. ncbi Endothelial loss and repair in the vascular complications of diabetes: pathogenetic mechanisms and therapeutic implications
    Richard E Gilbert
    Keenan Research Centre of the Li Ka Shing Knowledge Institute, St Michael s Hospital, Toronto, Ontario, Canada
    Circ J 77:849-56. 2013
  4. pmc A purpose-synthesised anti-fibrotic agent attenuates experimental kidney diseases in the rat
    Richard E Gilbert
    Keenan Research Centre, Li Ka Shing Knowledge Institute, St Michael s Hospital, Toronto, Ontario, Canada
    PLoS ONE 7:e47160. 2012
  5. doi Cell therapy for diabetic nephropathy: is the future, now?
    Richard E Gilbert
    Keenan Research Centre of the Li Ka Shing Knowledge Institute, St Michael s Hospital, Toronto, Ontario, Canada
    Semin Nephrol 32:486-93. 2012
  6. ncbi Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes
    Richard E Gilbert
    Department of Medicine, St Michael s Hospital, University of Toronto, Toronto, Ontario, Canada
    Diabetes Care 30:995-6. 2007
  7. ncbi Rosiglitazone: opening Pandora's black box?
    Richard E Gilbert
    Department of Medicine, St Michael s Hospital, 61 Queen Street, Toronto, Ontario, Canada, M5C 2T2
    Clin J Am Soc Nephrol 2:1329-31. 2007
  8. doi Inhibition of protein kinase C-beta by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy
    Kim A Connelly
    Keenan Research Centre in the Li Ka Shing Knowledge Institute, St Michael s Hospital, University of Toronto, Toronto, Canada
    Circ Heart Fail 2:129-37. 2009
  9. doi Inhibition of the epidermal growth factor receptor preserves podocytes and attenuates albuminuria in experimental diabetic nephropathy
    Andrew Advani
    Keenan Research Centre of the Li Ka Shing Knowledge Institute, St Michael s Hospital, Toronto, Ontario, Canada
    Nephrology (Carlton) 16:573-81. 2011
  10. doi Histone deacetylase inhibition attenuates diabetes-associated kidney growth: potential role for epigenetic modification of the epidermal growth factor receptor
    Richard E Gilbert
    Keenan Research Centre of the Li Ka Shing Knowledge Institute, St Michael s Hospital, Toronto, Ontario, Canada
    Kidney Int 79:1312-21. 2011

Collaborators

Detail Information

Publications53

  1. doi The endothelium in diabetic nephropathy
    Richard E Gilbert
    Keenan Research Centre of the Li Ka Shing Knowledge Institute, St Michael s Hospital, 61 Queen Street East, Toronto, Ontario, Canada, M5C 2 T2
    Curr Atheroscler Rep 16:410. 2014
    ..New treatments in diabetes that directly address the abnormal structure and function of the endothelial cell are desperately needed. ..
  2. doi Augmenting endothelial repair in diabetes: role of bone marrow-derived cells
    Richard E Gilbert
    Keenan Research Centre of the Li Ka Shing Knowledge Institute, St Michael s Hospital, University of Toronto, Ontario, Canada Electronic address
    Can J Diabetes 37:315-8. 2013
    ....
  3. ncbi Endothelial loss and repair in the vascular complications of diabetes: pathogenetic mechanisms and therapeutic implications
    Richard E Gilbert
    Keenan Research Centre of the Li Ka Shing Knowledge Institute, St Michael s Hospital, Toronto, Ontario, Canada
    Circ J 77:849-56. 2013
    ....
  4. pmc A purpose-synthesised anti-fibrotic agent attenuates experimental kidney diseases in the rat
    Richard E Gilbert
    Keenan Research Centre, Li Ka Shing Knowledge Institute, St Michael s Hospital, Toronto, Ontario, Canada
    PLoS ONE 7:e47160. 2012
    ....
  5. doi Cell therapy for diabetic nephropathy: is the future, now?
    Richard E Gilbert
    Keenan Research Centre of the Li Ka Shing Knowledge Institute, St Michael s Hospital, Toronto, Ontario, Canada
    Semin Nephrol 32:486-93. 2012
    ....
  6. ncbi Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes
    Richard E Gilbert
    Department of Medicine, St Michael s Hospital, University of Toronto, Toronto, Ontario, Canada
    Diabetes Care 30:995-6. 2007
  7. ncbi Rosiglitazone: opening Pandora's black box?
    Richard E Gilbert
    Department of Medicine, St Michael s Hospital, 61 Queen Street, Toronto, Ontario, Canada, M5C 2T2
    Clin J Am Soc Nephrol 2:1329-31. 2007
  8. doi Inhibition of protein kinase C-beta by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy
    Kim A Connelly
    Keenan Research Centre in the Li Ka Shing Knowledge Institute, St Michael s Hospital, University of Toronto, Toronto, Canada
    Circ Heart Fail 2:129-37. 2009
    ..One such target is the beta-isoform of protein kinase C (PKC), implicated in both the complications of diabetes and in cardiac dysfunction in the nondiabetic setting...
  9. doi Inhibition of the epidermal growth factor receptor preserves podocytes and attenuates albuminuria in experimental diabetic nephropathy
    Andrew Advani
    Keenan Research Centre of the Li Ka Shing Knowledge Institute, St Michael s Hospital, Toronto, Ontario, Canada
    Nephrology (Carlton) 16:573-81. 2011
    ..In the present study we sought to investigate the effects of long-term inhibition of the EGFR tyrosine kinase in an experimental model of diabetes that is characterized by angiotensin II dependent hypertension...
  10. doi Histone deacetylase inhibition attenuates diabetes-associated kidney growth: potential role for epigenetic modification of the epidermal growth factor receptor
    Richard E Gilbert
    Keenan Research Centre of the Li Ka Shing Knowledge Institute, St Michael s Hospital, Toronto, Ontario, Canada
    Kidney Int 79:1312-21. 2011
    ..Thus, early renal changes in diabetes are amenable to epigenetic intervention. Attenuating effects of HDAC inhibition, although multifactorial, are likely to be mediated in part through downregulation of the EGFR...
  11. pmc Culture-modified bone marrow cells attenuate cardiac and renal injury in a chronic kidney disease rat model via a novel antifibrotic mechanism
    Darren A Yuen
    Keenan Research Centre of the Li Ka Shing Knowledge Institute, St Michael s Hospital, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
    PLoS ONE 5:e9543. 2010
    ..In exploring the therapeutic potential of bone marrow derived cells in chronic cardio-renal disease, we examined the anti-fibrotic effects of bone marrow-derived culture modified cells (CMCs) and stromal cells (SCs)...
  12. pmc Early-outgrowth bone marrow cells attenuate renal injury and dysfunction via an antioxidant effect in a mouse model of type 2 diabetes
    Yanling Zhang
    Keenan Research Centre of the Li Ka Shing Knowledge Institute, St Michael s Hospital, University of Toronto, Toronto, Ontario, Canada
    Diabetes 61:2114-25. 2012
    ..The similarly beneficial effects of cells from healthy and diabetic donors highlight the potential of autologous cell therapy in the related clinical setting...
  13. pmc Long-term administration of the histone deacetylase inhibitor vorinostat attenuates renal injury in experimental diabetes through an endothelial nitric oxide synthase-dependent mechanism
    Andrew Advani
    Keenan Research Centre, Li Ka Shing Knowledge Institute, St Michael s Hospital, Toronto, Ontario, Canada
    Am J Pathol 178:2205-14. 2011
    ..These observations illustrate the therapeutic efficacy of long-term HDAC inhibition in diabetic nephropathy and emphasize the importance of the interplay between eNOS activity and oxidative stress in mediating these effects...
  14. pmc Expression, localization, and function of the thioredoxin system in diabetic nephropathy
    Andrew Advani
    Keenan Research Centre of the Li Ka Shing Knowledge Institute, St Michael s Hospital, Toronto, Ontario, Canada
    J Am Soc Nephrol 20:730-41. 2009
    ..Taken together, these findings suggest that impaired thiol reductive capacity contributes to the generation of reactive oxygen species in diabetes in a site- and cell-specific manner...
  15. pmc PKC-beta1 mediates glucose-induced Akt activation and TGF-beta1 upregulation in mesangial cells
    Dongcheng Wu
    Division of Nephrology, McMaster University, Hamilton, Ontario, Canada
    J Am Soc Nephrol 20:554-66. 2009
    ..New therapeutic approaches for diabetic nephropathy may result from targeting components of this pathway, particularly the initial EGFR transactivation...
  16. pmc Angiogenic dysfunction in bone marrow-derived early outgrowth cells from diabetic animals is attenuated by SIRT1 activation
    Darren A Yuen
    Department of Medicine, St Michael s Hospital, Ontario, Canada
    Stem Cells Transl Med 1:921-6. 2012
    ..These findings suggest a pivotal role for SIRT1 in diabetes-induced EOC dysfunction and that its pharmacologic activation may provide a new strategy for the restoration of EOC-mediated repair mechanisms...
  17. doi Bone marrow cell therapies for endothelial repair and their relevance to kidney disease
    Darren A Yuen
    Keenan Research Centre, Li Ka Shing Knowledge Institute, St Michael s Hospital, University of Toronto, Toronto, Ontario, Canada
    Semin Nephrol 32:215-23. 2012
    ..To harness the prognostic and therapeutic potential of the bone marrow, the renal community must be aware of recent advances in our understanding of the nature and therapeutic potential of these cells...
  18. pmc Fluorescent microangiography is a novel and widely applicable technique for delineating the renal microvasculature
    Andrew Advani
    Keenan Research Centre of the Li Ka Shing Knowledge Institute, St Michael s Hospital, Toronto, Ontario, Canada
    PLoS ONE 6:e24695. 2011
    ..FMA is an uncomplicated technique for evaluating the renal microvasculature that circumvents many of the limitations imposed by conventional analysis of two-dimensional tissue sections...
  19. doi Early outgrowth cells release soluble endocrine antifibrotic factors that reduce progressive organ fibrosis
    Darren A Yuen
    Keenan Research Centre of the Li Ka Shing Knowledge Institute, St Michael s Hospital, Toronto, Ontario, Canada
    Stem Cells 31:2408-19. 2013
    ..Together, these findings suggest that an endocrine mode of action may underlie the effectiveness of cell therapy in certain settings and portend the possibility for systemic delivery of cell-free therapy...
  20. pmc Role of the eNOS-NO system in regulating the antiproteinuric effects of VEGF receptor 2 inhibition in diabetes
    Andrew Advani
    Keenan Research Centre of the Li Ka Shing Knowledge Institute, St Michael s Hospital, 6 151, 61 Queen Street East, Toronto, ON, Canada M5C 2T2
    Biomed Res Int 2013:201475. 2013
    ..These observations highlight the pivotal role that the eNOS-NO system plays in regulating the biologic response to VEGF within the glomerulus. ..
  21. doi The (Pro)renin receptor: site-specific and functional linkage to the vacuolar H+-ATPase in the kidney
    Andrew Advani
    Keenan Research Centre of the Li Ka Shing Knowledge Institute, St Michael s Hospital, 61 Queen St East, Toronto, Ontario, Canada M5C 2T2
    Hypertension 54:261-9. 2009
    ....
  22. pmc Hyperglycemia and renal mass ablation synergistically augment albuminuria in the diabetic subtotally nephrectomized rat: implications for modeling diabetic nephropathy
    Li Hao Chen
    Keenan Research Centre of the Li Ka Shing Knowledge Institute, St Michael s Hospital, Toronto, Ont, Canada
    Nephron Extra 2:115-24. 2012
    ..Accordingly, in the present study, we combined streptozotocin-induced diabetes with surgical ablation of 5/6 of the kidney mass with the aim of evaluating their additive effects on renal function and glomerular morphology...
  23. doi The cardiac (pro)renin receptor is primarily expressed in myocyte transverse tubules and is increased in experimental diabetic cardiomyopathy
    Kim A Connelly
    Keenan Research Centre in the Li Ka Shing Knowledge Institute, St Michael s Hospital and University of Toronto, Toronto, Canada
    J Hypertens 29:1175-84. 2011
    ..While implicated in a broad range of diseases, studies to date have focused on the kidney, particularly in the diabetic context. We sought to examine the site-specific expression of the pro(renin) receptor within the heart...
  24. doi DPP-4 inhibition attenuates cardiac dysfunction and adverse remodeling following myocardial infarction in rats with experimental diabetes
    Kim Alexander Connelly
    Keenan Research Centre of the Li Ka Shing Knowledge Institute, St Michael s Hospital, Toronto, Ontario, Canada
    Cardiovasc Ther 31:259-67. 2013
    ..Accordingly, we hypothesized that inhibiting this enzyme may confer benefit following myocardial infarction in the diabetic setting beyond its effect on glycemia...
  25. doi The endothelium in diabetic nephropathy
    Andrew Advani
    Keenan Research Centre of the Li Ka Shing Knowledge Institute, St Michael s Hospital, and Department of Medicine, University of Toronto, Toronto, Ontario, Canada
    Semin Nephrol 32:199-207. 2012
    ..Such advances likely will lead not only to improved tissue oxygenation and reduced fibrosis, but also to improved long-term renal function...
  26. pmc The CXCR4/CXCR7/SDF-1 pathway contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome in humans and mice
    Tania N Petruzziello-Pellegrini
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
    J Clin Invest 122:759-76. 2012
    ..Collectively, these data implicate the CXCR4/CXCR7/SDF-1 pathway in Stx-mediated pathogenesis and suggest novel therapeutic strategies for prevention and/or treatment of complications associated with E. coli O157:H7 infection...
  27. pmc Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions
    Andrew Advani
    Department of Medicine, University of Toronto, St Michael s Hospital, Toronto, ON, Canada M5C 2T2
    Proc Natl Acad Sci U S A 104:14448-53. 2007
    ....
  28. doi Activated protein C and diabetic nephropathy
    Richard E Gilbert
    Keenan Research Centre of the Li Ka Shing Knowledge Institute and the Division of Endocrinology, St Michael s Hospital, Toronto
    N Engl J Med 358:1628-30. 2008
  29. ncbi Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension
    Darren J Kelly
    Department of Medicine, University of Melbourne, St Vincent s Hospital, Fitzroy, Victoria, Australia
    Diabetes 52:512-8. 2003
    ..In vivo inhibition of PKC beta with LY333531 led to a reduction in albuminuria, structural injury, and TGF-beta expression, despite continued hypertension and hyperglycemia...
  30. ncbi Protein kinase Cbeta inhibition attenuates osteopontin expression, macrophage recruitment, and tubulointerstitial injury in advanced experimental diabetic nephropathy
    Darren J Kelly
    Department of Medicine, University of Melbourne, St Vincent s Hospital, Fitzroy, Victoria, Australia, 3065
    J Am Soc Nephrol 16:1654-60. 2005
    ....
  31. ncbi Urinary connective tissue growth factor excretion in patients with type 1 diabetes and nephropathy
    Richard E Gilbert
    Department of Medicine, St Vincent s Hospital, University of Melbourne, Fitzroy, Australia
    Diabetes Care 26:2632-6. 2003
    ..In this cross-sectional study, we sought to examine the urinary excretion of the profibrotic cytokine connective tissue growth factor (CTGF) in type 1 diabetic patients with incipient and overt diabetic nephropathy...
  32. ncbi Transforming growth factor-beta in human diabetic nephropathy: effects of ACE inhibition
    Robyn G Langham
    University of Melbourne, Department of Medicine, St Vincent s Hospital, Australia
    Diabetes Care 29:2670-5. 2006
    ..However, the role of the RAS blockade in abrogating TGF-beta in human disease is unknown. Accordingly, we sought to examine TGF-beta gene expression and biological activity in human renal biopsies, before and after ACE inhibition...
  33. ncbi Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction
    Christine A Houlihan
    University of Melbourne, Department of Medicine at Austin, Victoria, Australia
    Diabetes Care 25:1072-7. 2002
    ....
  34. ncbi Effects on protein kinase C-beta inhibition on glomerular vascular endothelial growth factor expression and endothelial cells in advanced experimental diabetic nephropathy
    Darren J Kelly
    Dept of Medicine, St Vincent s Hospital, Fitzroy, Victoria 3065, Australia
    Am J Physiol Renal Physiol 293:F565-74. 2007
    ..Combination therapy was also associated with additional improvements in albuminuria and glomerulosclerosis...
  35. ncbi Inhibition of protein kinase C reduces left ventricular fibrosis and dysfunction following myocardial infarction
    Andrew J Boyle
    Department of Medicine, St Vincent s Hospital, University of Melbourne, Melbourne, Princes Street, Fitzroy 3065, Vic, Australia
    J Mol Cell Cardiol 39:213-21. 2005
    ..PKC-inhibition with ruboxistaurin led to attenuation in both the pathological fibrosis and impaired cardiac function that follow experimental MI, suggesting a possible role for this agent in preventing post-infarction heart failure...
  36. ncbi Mast cell infiltration and chemokine expression in progressive renal disease
    Susan E Jones
    University of Melbourne, Department of Medicine, St Vincent s Hospital, Fitzroy, Victoria, Australia
    Kidney Int 64:906-13. 2003
    ..Mast cells are growth factor-rich, bone marrow-derived cells that infiltrate injured tissue where they have been implicated in the pathogenesis of progressive fibrosis...
  37. ncbi Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy
    Alex Tzanidis
    NHMRC Centre of Clinical Research Excellence in Therapeutics, Department of MedicineEpidemiology and Preventive Medicine, Monash University Medical School, Prahran, Victoria, Australia
    Circ Res 93:246-53. 2003
    ....
  38. ncbi Over-expression of platelet-derived growth factor in human diabetic nephropathy
    Robyn G Langham
    University of Melbourne St Vincent s Hospital Department of Medicine, Fitzroy, Australia
    Nephrol Dial Transplant 18:1392-6. 2003
    ..In this study, the gene expression and protein distribution of platelet-derived growth factor-A and -B (PDGF-A and PDGF-B) in human diabetic nephropathy were examined...
  39. ncbi High glucose induces macrophage inflammatory protein-3 alpha in renal proximal tubule cells via a transforming growth factor-beta 1 dependent mechanism
    Weier Qi
    Kolling Institute, Department of Medicine, Royal North Shore Hospital, St Leonards, NSW, Australia
    Nephrol Dial Transplant 22:3147-53. 2007
    ..Transforming growth factor-beta1 (TGF-beta1) is a key regulator in inflammation and fibrosis in diabetes mellitus setting...
  40. ncbi Expression of the slit-diaphragm protein, nephrin, in experimental diabetic nephropathy: differing effects of anti-proteinuric therapies
    Darren J Kelly
    University of Melbourne Department of Medicine at St Vincent s Hospital, Fitzroy, Victoria, Australia
    Nephrol Dial Transplant 17:1327-32. 2002
    ..In addition, the study also sought to examine nephrin expression in animals treated with different anti-proteinuric therapies...
  41. ncbi Progression of tubulointerstitial injury by osteopontin-induced macrophage recruitment in advanced diabetic nephropathy of transgenic (mRen-2)27 rats
    Darren J Kelly
    Department of Medicine, University of Melbourne, St Vincent s Hospital, Fitzroy, Australia
    Nephrol Dial Transplant 17:985-91. 2002
    ..Osteopontin is a macrophage chemotactic protein that has been pathogenetically linked to tissue injury in non-diabetic kidney disease...
  42. ncbi Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy
    Sally Mifsud
    Department of Physiology, University of Melbourne and St Vincent s Hospital, Melbourne, Vic, Australia
    Nephron Physiol 95:p83-91. 2003
    ..However, its effects on diabetic renal pathology are unknown...
  43. ncbi Fas-induced apoptosis is a feature of progressive diabetic nephropathy in transgenic (mRen-2)27 rats: attenuation with renin-angiotensin blockade
    Darren J Kelly
    Department of Medicine, University of Melbourne, St Vincent s Hospital, Fitzroy, Melbourne, Victoria, Australia
    Nephrology (Carlton) 9:7-13. 2004
    ..The effects of renoprotective therapy with blockade of the renin-angiotensin (RAS) system were also examined...
  44. pmc Inhibition of platelet-derived growth factor promotes pericyte loss and angiogenesis in ischemic retinopathy
    Jennifer L Wilkinson-Berka
    Department of Physiology, University of Melbourne, Parkville, Victoria, Australia
    Am J Pathol 164:1263-73. 2004
    ..In conclusion, PDGF is required for pericyte viability and the subsequent prevention of VEGF/VEGFR-2 overexpression and angiogenesis in ROP...
  45. ncbi Progressive diabetic nephropathy in the Ren-2 rat
    Darren J Kelly
    Am J Physiol Renal Physiol 292:F1662; author reply F1663. 2007
  46. ncbi Transforming growth factor-beta1 differentially mediates fibronectin and inflammatory cytokine expression in kidney tubular cells
    Weier Qi
    Dept of Medicine, Level 3, Wallace Freeborn Professorial Block, Royal North Shore Hospital, St Leonards, NSW, Australia
    Am J Physiol Renal Physiol 291:F1070-7. 2006
    ..Conversely, decreased expression of TGF-beta(1) results in increased TGF-beta(2), TGF-beta(3), AP-1, and pSmad2 that potentially mediates the observed increase in fibronectin...
  47. ncbi TGF-beta1 induces IL-8 and MCP-1 through a connective tissue growth factor-independent pathway
    Weier Qi
    Department of Medicine, Kolling Institute, University of Sydney, Royal North Shore Hospital, St Leonards, NSW 2065, Australia
    Am J Physiol Renal Physiol 290:F703-9. 2006
    ..TGF-beta mediates both fibrosis and chemokine production in the proximal tubule of the kidney. However, CTGF plays a more specific role as a downstream mediator of TGF-beta(1)-induced fibrosis...
  48. ncbi Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations
    Marc A Pohl
    Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk A51, Cleveland, OH 44195, USA
    J Am Soc Nephrol 16:3027-37. 2005
    ..There was no correlation between diastolic BP and renal outcomes. We recommend a SBP target between 120 and 130 mmHg, in conjunction with blockade of the renin-angiotensin system, in patients with type 2 diabetic nephropathy...
  49. ncbi High glucose transactivates the EGF receptor and up-regulates serum glucocorticoid kinase in the proximal tubule
    Sonia Saad
    Kolling Institute Royal North Shore Hospital, University of Sydney, Sydney, Australia
    Kidney Int 68:985-97. 2005
    ..As the epidermal growth factor (EGF) receptor is activated by both EGF and other factors implicated in diabetic nephropathy, the relationship of SGK-1 with EGFR activity was assessed...
  50. ncbi Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-beta
    Jennifer Martin
    University of Melbourne, Department of Medicine, St Vincent s Hospital, Victoria, Australia
    Cardiovasc Res 65:694-701. 2005
    ..Tranilast (n-[3,4-anthranilic acid), used for the treatment of fibrotic skin diseases, has also been shown to inhibit transforming growth factor-beta (TGF-beta)-induced matrix production in kidney epithelial cells...
  51. ncbi Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy
    Robyn G Langham
    University of Melbourne Department of Medicine, St Vincent s Hospital, Fitzroy, Victoria, Australia
    Am J Kidney Dis 44:826-31. 2004
    ..Accordingly, the present study sought to examine the expression and localization of UII and its receptor in kidney tissue from patients with diabetic nephropathy...
  52. ncbi Tranilast attenuates structural and functional aspects of renal injury in the remnant kidney model
    Darren J Kelly
    University of Melbourne, Department of Medicine, St Vincent s Hospital, Victoria, Australia
    J Am Soc Nephrol 15:2619-29. 2004
    ..In the context of a recent pilot study in humans, the findings of the present report suggest that tranilast may provide a novel strategy for the treatment of progressive kidney disease characterized by fibrotic scarring...
  53. ncbi Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats
    Darren J Kelly
    Department of Medicine, St Vincent s Hospital, Fitzroy, Victoria, Australia
    Kidney Int 61:31-9. 2002
    ..The effects of renoprotective therapy with blockade of the renin-angiotensin system (RAS) also were examined...